Login to Your Account



Other news to note


Monday, July 14, 2014
Brainstorm Cell Therapeutics Inc., of New York and Petach Tikvah, Israel, said details of a preclinical study describing the safety of single and repeated intramuscular administration of Nurown, its mesenchymal stem cells, have been published in Clinical and Translational Medicine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription